New hope for advanced prostate cancer: enhertu trial launches
NCT ID NCT06610825
First seen Apr 17, 2026 · Last updated May 13, 2026 · Updated 2 times
Summary
This study tests the drug Enhertu in 60 men with a specific type of advanced prostate cancer (HER2-positive) that has stopped responding to standard hormone therapy and chemotherapy. The goal is to see if Enhertu can shrink tumors or slow the cancer's growth. Participants must have a life expectancy of at least 6 months and good organ function.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Washington DC VAMC
RECRUITINGWashington D.C., District of Columbia, 20422, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.